ARDS kills between 30% and 50% of the people it affects, even in modern intensive care units, and that mortality rate has changed little in decades. Researchers at the University at Buffalo are now exploring whether a fatty acid found in salmon and other fatty fish could be used to interrupt the process by which injured lungs keep destroying themselves – not by suppressing the immune system, but by prompting immune cells already inside the lungs to produce molecules that signal inflammation to end.
The approach is experimental, still years from any clinic, and its real value will only become clear once animal testing is complete. The biological rationale behind it, however, is grounded in established chemistry and targets a problem current medicine has largely failed to solve.
Acute respiratory distress syndrome is a life-threatening condition characterized by poor oxygenation and stiff lungs, associated with endothelial injury and diffuse alveolar damage. It can follow pneumonia, COVID-19, sepsis, and other serious illnesses, leaving patients unable to get enough oxygen without medical support. ARDS affects more than 200,000 people annually in the United States, and of those, 30% to 50% die.
Why the Lung Keeps Failing Even After Treatment
The current standard of care for ARDS is largely mechanical and supportive. Clinicians ventilate the patient, manage the underlying illness, and wait for the lungs to recover. When inflammation is especially severe, corticosteroids are sometimes used – but that approach carries a real drawback. Strongly suppressing the immune response can make patients more susceptible to secondary infections, leaving clinicians without a reliable tool to control the inflammatory damage without creating new vulnerability.
Rapid recruitment of neutrophils – the immune cells that rush to sites of infection or injury – is one of the hallmarks of an effective immune response. Neutrophils migrate to inflamed lung tissue and release substances that damage surrounding tissue when the response becomes excessive or prolonged. In ARDS, large numbers of these cells accumulate in the lungs and amplify, rather than control, the destruction.
Healthy lungs contain millions of tiny air sacs called alveoli, surrounded by fine blood vessels, where oxygen diffuses across thin walls into the bloodstream. Severe inflammation breaks down the barrier separating those air sacs from blood vessels, allowing fluid to fill the spaces where oxygen should move. Breathing becomes progressively harder, and the effects extend to organs throughout the body.
The DHA-Resolvin Connection and the Fatty Fish Lung Injury Research
Fatty fish such as salmon are high in omega-3 fatty acids. A 100g portion of farmed salmon contains approximately 2g of the omega-3 fatty acids EPA and DHA combined. DHA, or docosahexaenoic acid, has attracted research attention for its anti-inflammatory properties, but its role in the lungs is more specific than general supplementation studies might suggest.
A study funded largely by the National Heart, Lung, and Blood Institute and published in the American Journal of Respiratory and Critical Care Medicine found that higher blood levels of omega-3 fatty acids were associated with a slower rate of lung function decline in adults, with the strongest associations observed for DHA, an omega-3 fatty acid found in foods such as fatty fish.
Once DHA enters cells, it can serve as the starting material for molecules called resolvins. Resolvins RvD1 and RvD2 are derived from DHA and help signal that an inflammatory response should wind down. These molecules are not simply anti-inflammatory in the conventional sense: resolvins help the body actively clear inflammatory debris and initiate tissue repair in experimental animal models, while allowing immune defenses to remain intact – a different mechanism from broadly suppressing immune activity.
The practical difficulty with using resolvins directly as medicines is that the molecules are inherently unstable, making them difficult to manufacture in consistent doses and deliver reliably to the right location inside the body.
Delivering DHA Directly Inside Inflamed Lung Cells
Dr. Zhenjia Wang, a nanomedicine researcher and Associate Professor in the Department of Pharmaceutical Sciences at the University at Buffalo, is pursuing a different approach: delivering DHA directly into neutrophils already gathered around injured lung tissue, and letting the cells produce resolvins on their own.
Wang received a $2 million, four-year grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to pursue this research.
The delivery mechanism relies on liposomes – tiny fat-based spheres already used in clinical medicine – engineered to carry DHA to neutrophils concentrating around inflamed blood vessels in the lungs. Once inside the neutrophil, the body’s own enzymatic chemistry converts DHA into resolvins. If that conversion happens reliably and at sufficient scale, therapeutic resolvin production would occur directly at the site of lung injury rather than being manufactured externally and transported through the whole body. That localization could reduce the risk of systemic side effects that complicate many current ARDS treatments.
Wang’s colleague Elsa Bou Ghanem, an Associate Professor in the Department of Microbiology and Immunology at the University at Buffalo, brings expertise in immunology and neutrophil biology to the collaboration. Because neutrophils play a central role in many inflammatory conditions, the researchers have noted the approach could eventually extend beyond ARDS if the core mechanism proves effective.
What the Animal Studies Will Actually Test
Researchers will use mouse models of acute lung injury to test the treatment over the four-year grant period. They have three main goals: to develop the most effective liposomes for delivering DHA directly to neutrophils; to determine whether those neutrophils produce more resolvins after receiving DHA; and to assess whether the treatment improves outcomes in the animal models.
Each of those steps is a genuine hurdle. Nanoparticles that target specific cell types in laboratory conditions don’t always behave the same way in the complex, highly variable environment of a living animal’s inflamed lung. Researchers must also determine whether the quantity of resolvins produced is clinically meaningful, and whether the approach is safe across the range of dosing and delivery variables they will test.
ARDS mortality, sustained across decades despite advances in critical care, is part of what makes this line of research worth pursuing – even knowing that most experimental approaches don’t advance past animal models. The omega-3 and resolvin pathway has a solid mechanistic rationale and prior preclinical evidence behind it, but that history also includes failed clinical trials with omega-3 supplements delivered systemically rather than targeted to specific cells.
This research connects to a broader body of evidence linking omega-3 fatty acids to respiratory health. The NHLBI-funded observational study established an association between higher blood levels of DHA and slower lung function decline in healthy adults – but that was a finding about healthy lungs, not a treatment for acute lung failure. Wang’s research targets a different and far more immediate problem: stopping catastrophic lung destruction in critically ill patients.
Read More: Not Just Salmon: These 6 Fish Are Omega-3 Powerhouses
What This Means for You
This research is firmly in the experimental phase. No human trials have been announced, and the DHA-liposome treatment is not available in any clinical setting. For anyone who develops severe pneumonia, COVID-19, or sepsis leading to acute lung injury, the current standard of care – mechanical ventilation, careful fluid management, and close ICU monitoring – remains the only proven approach.
The University at Buffalo project offers a genuinely different direction. Rather than suppressing the immune system broadly, it attempts to use the body’s own biochemical signals to guide inflammation toward resolution. If the mouse studies confirm that DHA-loaded liposomes reach neutrophils effectively and generate measurable resolvin production, the research team will have a scientific foundation to justify moving toward human safety trials – a multi-year path at minimum.
The broader omega-3 evidence does support regular consumption of fatty fish like salmon, tuna, sardines, and mackerel as part of a diet that may support lung health over time. The U.S. Dietary Guidelines recommend at least two servings of fish per week, and DHA from food is the most direct route to maintaining adequate blood levels of this fatty acid. That is not a treatment for ARDS, but it may support the immune system’s natural resolution pathways over time.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.